Human Anti-TNFRSF12A Recombinant Antibody (clone TPP-2090) (CAT#: HPAB-0049-LSX)

Clone TPP-2090 is a human monoclonal antibody that binds to TWEAKR. TPP-2090 can be potentially used in the treatment studies of tumors and other disorders and conditions associated with expression of the TWEAKR.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 Interaction of TWEAKR ectodomain with antibodies and reference antibodies.

Figure 1 Interaction of TWEAKR ectodomain with antibodies and reference antibodies.

Shown is the result of an ELISA with TWEAKR-Fc fusion protein (TPP-2202) coating (1 mg/ml) and 0.08 mg/ml (open bars) and 0.3 mg/ml (filled bars) of biotinylated IgG as soluble binding partner. Detection was done with Streptavidin-HRP and Amplex-Red substrate. Y is "ELISA signal intensity [Rfu]"; X are "antibody constructs tested": a is "TPP-2090"; b is "TPP-2084"; c is "PDL-192(TPP-1104)"; d is "P4A8(TPP-1324)"; e is "P3G5(TPP-2195)"; f is "136.1(TPP-2194)"; h is "ITEM1"; i is "ITEM4"; j is a murine isotype control; k is a human isotype control. All tested antibodies show saturated binding with a concentration of 80 ng/ml.

ELISA

Figure 2 Interaction of TWEAKR cysteine rich domain with antibodies and reference antibodies.

Figure 2 Interaction of TWEAKR cysteine rich domain with antibodies and reference antibodies.

Shown is the result of an ELISA with TWEAKR(34-68)-Fc fusion protein (TPP-2203) coating (1 mg/ml) and 0.08 mg/ml (open bars) and 0.3 mg/ml (filled bars) of biotinylated IgG as soluble binding partner. Detection was done with Streptavidin-HRP and Amplex-Red substrate. Y is "ELISA signal intensity [Rfu]"; X are "antibody constructs tested": a is "TPP-2090"; b is "TPP-2084"; c is "PDL-192(TPP-1104)"; d is "P4A8(TPP-1324)"; e is "P3G5(TPP-2195)"; f is "136.1(TPP-2194)"; h is "ITEM1"; i is "ITEM4"; j is a murine isotype control; k is a human isotype control. The antibodies bind to the cysteine rich domain.

FuncS

Figure 3 Induction of Stat-1 and NF-kappaB2 signaling pathways by anti-TWEAKR antibodies in vivo.

Figure 3 Induction of Stat-1 and NF-kappaB2 signaling pathways by anti-TWEAKR antibodies in vivo.

Treatment of mice started at day 7 after tumor cell inoculation and lysates were prepared from snap frozen tumors taken at the end of the study (day 29). Blots from 2 representative animals per group are shown. Treatment with TPP-2090 leads to a strong induction of P-Stat 1 & Total Stat 1 levels as well as NF-kappaB2 activation (shown by the appearance of the p52 band) in WiDr xenograft tumors. Lysates of snap frozen WiDr xenograft tumors after treatment with PBS (i.v., q4dx7: lanes 1&2) or TPP-2090 (3 mg/kg, i.v., q4dx7: lanes 3&4) were subjected to Western Blot analysis detected with specific antibodies for P-Stat 1 (a), Stat-1 (b), NF-kappa2-p52 (c) and GAPDH (d).

FuncS

Figure 4 Efficacy of 10 mg/kg TPP-2090 (i.v., q4dx8) in the human lung cancer xenograft NCI-H322 in monotherapy and combination therapy with Paclitaxel (16 mg/kg, i.v., q7dx4).

Figure 4 Efficacy of 10 mg/kg TPP-2090 (i.v., q4dx8) in the human lung cancer xenograft NCI-H322 in monotherapy and combination therapy with Paclitaxel (16 mg/kg, i.v., q7dx4).

Treatment started 14d after inoculation with established tumors of about 45 mm2. A is "Vehicle group, treated with PBS (i.v. q4dx8)". B is "TPP-2090, 5 mg/kg", C is "TPP-2090, 10 mg/kg", D is "Paclitaxel, 16 mg/kg", E is "Combo TPP-2090 10 mg/kg+Paclitaxel 16 mg/kg". (X is "Time after inoculation [days]"; Y is "Tumor area, means of n=10; SD [mm²]")

FuncS

Figure 5 Efficacy of anti-TWEAKR antibodies in the human renal cell cancer xenograft 786-O after treatment with 0.3, 1.0 and 3.0 mg/kg (i.v., q4dx3) started at day 7 after tumor cell inoculation.

Figure 5 Efficacy of anti-TWEAKR antibodies in the human renal cell cancer xenograft 786-O after treatment with 0.3, 1.0 and 3.0 mg/kg (i.v., q4dx3) started at day 7 after tumor cell inoculation.

Shown are final tumor weights at day 40. A is "Vehicle group, treated with PBS (i.v. q4dx3)". B is "Isotype, 3 mg/kg", C is "TPP-2084, 0.3 mg/kg", D is "TPP-2084, 1 mg/kg", E is "TPP-2084, 3 mg/kg", F is "TPP-2090, 0.3 mg/kg", G is "TPP-2090, 1 mg/kg", H is "TPP-2090, 3 mg/kg". (Y is "Tumor weights means of n=8; SD [g]").


Specifications

  • Immunogen
  • Dimeric Fc-fused extracellular domains of human and murine TWEAK
  • Host Species
  • Human
  • Type
  • Human IgG
  • Specificity
  • Human TNFRSF12A
  • Species Reactivity
  • Human, Rat, Mouse, Canine, Porcine, Monkey
  • Clone
  • TPP-2090
  • Applications
  • ELISA, WB, FC, FuncS
  • Related Disease
  • Tumors and other disorders and conditions associated with expression of the TWEAKR

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • This antibody has been tested for use in Enzyme-linked Immunosorbent Assay (80 ng/ml), Functional Assay.

Target

  • Alternative Names
  • FN14; CD266; TWEAKR

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone TPP-2090"

See other products for "TNFRSF12A"

Immunotoxin

CAT Product Name Application Type
AGTO-G061G Anti-TNFRSF12A immunotoxin ITEM-4 (scFv)-Gel Cytotoxicity assay, Function study

Chimeric Antibody

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-194LC Recombinant Anti-Human TNFRSF12A Antibody (Non-glycosylated) ELISA Humanized antibody

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-3610 Rabbit Anti-TNFRSF12A Recombinant Antibody (clone DS3610AB) IHC-P, WB Rabbit IgG

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for HPAB-0049-LSX. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare